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A B S T R A C T
Purpose
Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations are
frequently observed in primary breast cancer. We evaluated their prognostic relevance by per-
forming a pooled analysis of individual patient data.
Patients and Methods
Associations between PIK3CA status and clinicopathologic characteristics were tested by applying
Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status,
human epidermal growth factor receptor 2 (HER2) status, treatment, and study. Invasive disease-
free survival (IDFS) was the primary end point; distant disease-free survival (DDFS) and overall
survival (OS) were also assessed, overall and by breast cancer subtypes.
Results
Data from 10,319 patients from 19 studies were included (median OS follow-up, 6.9 years); 1,787
patients (17%) received chemotherapy, 4,036 (39%) received endocrine monotherapy, 3,583 (35%)
received both, and 913 (9%) received none or their treatment was unknown. PIK3CA mutations
occurred in 32% of patients, with signiﬁcant associations with ER positivity, increasing age, lower
grade, and smaller size (all P, .001). Prevalence of PIK3CAmutationswas 18%, 22%, and 37% in the
ER-negative/HER2-negative, HER2-positive, and ER-positive/HER2-negative subtypes, respectively. In
univariable analysis, PIK3CA mutations were associated with better IDFS (HR, 0.77; 95% CI, 0.71 to
0.84;P, .001), with evidence for a stronger effect in the ﬁrst years of follow-up (0 to 5 years: HR, 0.73;
95% CI, 0.66 to 0.81; P , .001; 5 to 10 years: HR, 0.82; 95% CI, 0.68 to 0.99; P = .037); . 10 years:
(HR, 1.15; 95% CI, 0.84 to 1.58; P = .38; P heterogeneity = .02). In multivariable analysis, PIK3CA
genotype remained signiﬁcant for improved IDFS (P = .043), but not for the DDFS and OS end points.
Conclusion
In this large pooled analysis, PIK3CA mutations were signiﬁcantly associated with a better IDFS,
DDFS, and OS, but had a lesser prognostic effect after adjustment for other prognostic factors.
J Clin Oncol 36:981-990. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Phosphatidylinositol-4, 5-bisphosphate 3-kinase
catalytic subunit alpha (PIK3CA) mutations affect
the gene corresponding to the alpha isoform of
the catalytic subunit (p110) of the class IA kinase
and has been extensively studied for its role in
human carcinogenesis.1 These mutations have
been reported in a variety of human cancers,
including colorectal, endometrial, and ovarian
cancer, among others.2-4 In primary breast cancer
(BC), PIK3CA mutations are frequent, with the
highest frequency among the hormone receptor–
positive tumors.5-7 Approximately 80% of mu-
tations cluster in hot spots located within the
helical domain and the kinase domain. The
functional consequences of these hot-spot mu-
tations have been studied extensively at the pre-
clinical level, indicating that they are potent
mediators of oncogenesis through AKTactivation
and evasion of apoptosis, as well as induction of
an invasive and migratory phenotype.8-11 In ad-
dition, PIK3CAmutations have been associated at
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the preclinical and clinical level with resistance to paclitaxel,
trastuzumab, and endocrine treatment.9,12-15
On the basis of the high frequency of PIK3CAmutations in BC, as
well as the preclinical data supporting their multifaceted oncogenic
functions, several studies have assessed their clinical relevance for patients
with early-stage disease.16 In particular, their prognostic relevance has
been evaluated with conﬂicting results.15 Of note, many of these studies
were conducted among heterogeneous patient populations in terms of
BC subtypes and treatments received, with some notable exceptions.17,18
Therefore, in this study, we pooled individual patient data from these
previous studies of patients with early-stage BC to robustly evaluate the
prognostic associations of these commonly occurring aberrations (and
hence their potential relevance for clinical decision making) overall by
mutation gene location as well as interactions by BC subtype.
PATIENTS AND METHODS
Types of Studies and Search Strategies
Potentially eligible studies were retrieved through an electronic search
on PubMed/MEDLINE using the MeSH terms “breast neoplasm” and
“PIK3CA protein, human.” The literature search was conducted in-
dependently by two investigators (D.Z. and D.F.) in January 2013. Iden-
tiﬁed studies were eligible for this pooled analysis of individual patient data
if they met the following requirements: (1) studies conducted in patients
with early-stage BC assessing the PIK3CA genotype in primary breast
tumor, (2) studies comparing clinical outcomes in association with the
PIK3CA genotype, and (3) studies published in the English language.
There were no restrictions for inclusion in our study in terms of
number of patients included, duration of follow-up, prospective versus ret-
rospective nature of the study, patients’ age, menopausal status, BC subtype, or
treatmentmodalities applied. In addition, no restrictions were applied in terms
of PIK3CAmutational status assessment method. However, studies conducted
in the neoadjuvant setting associating the PIK3CA genotype with pathologic
complete response rate without reporting results of further clinical outcome
were excluded from this pooled analysis. Cross-referencing from relevant
studies was performed to conﬁrm retrieval of all potentially eligible studies. In
terms of study eligibility, ﬁnal decisions were taken on consensus between the
two investigators who performed the research.
The investigators of the eligible trials were contacted and requested to
provide individual patient data on (1) baseline characteristics, including patients’
demographics and clinicopathologic characteristics; (2) PIK3CA genotype and
method used; (3) type of (neo)-adjuvant treatment received; (4) clinical out-
come, including type and time of event that occurred; and (5) survival status.
Individual patient data were used for all analyses, rather than combining results
as in the usual types of meta-analyses (Data Supplement; Fig 1).17-31
Statistical Analysis
The primary objective of this study was to assess the potential impact
of PIK3CA mutations on invasive disease-free survival (IDFS), and sec-
ondary objectives were to assess the prognostic impact in terms of distant
disease-free survival (DDFS) and overall survival (OS).
IDFS was deﬁned as the time from diagnosis until local, regional, or
distant recurrence; contralateral BC; second primary malignancy; or
death.32 IDFS analysis time was censored at the last date the patient was
known to be alive and recurrence free. DDFS included only distant re-
currence and death as events.32 DDFS analysis time was censored at the
date last known to be alive and distant recurrence free. OS included only
death as the event; patients were censored at the date last known to be alive.
Differences in patient and tumor characteristics byPIK3CAmutation status
were assessed usingx2 tests for categorical variables, the Cochran-Armitage trend
test for ordinal variables, and the Wilcoxon rank sum test for continuous
variables. Cox proportional hazard models were used to assess associations
betweenPIK3CAmutation status and IDFS,DDFS, andOS.Hazard ratios (HRs)
and 95% CIs were estimated from univariable and multivariable models.
Multivariablemodels included age (ﬁtted as cubic splines because the effect of age
on prognosis is U-shaped), stratiﬁed on tumor size (T1/T2/T3/T4), positive
nodes (yes/no), local histologic grade (1 to 2/3 to 4), estrogen receptor (ER) and
human epidermal growth factor receptor 2 (HER2) status (positive/negative),
and treatment (chemotherapy/endocrine therapy/both). Variables for which
the proportional hazards assumption was violated were included as strata
rather than covariables. The global test of proportional hazards was not vi-
olated for any of the results presented below, unless stated otherwise. We used
time intervals deﬁned by the Early Breast Cancer Trialists’Collaborative Group
to subdivide the time scale (0 to 5, 5 to 10, and . 10 years).33 Exploratory
objectives were to explore interactions between PIK3CA genotype and clinical
outcome according to BC subtype (deﬁned using ER and HER2 status), age,
and the possible impact of PIK3CA genotypes on the timing of recurrence
(early v late). Median follow-up time was calculated using the reverse Kaplan-
Meier method. All data analyses were conducted in R, version 3.1.2.
RESULTS
Patient Characteristics
Data on 10,319 patients with known PIK3CA genotype
originating from 19 studies were available (Fig 1; Data
Articles identified through
MEDLINE searching
(N = 97)
7 investigators declined
participation, 2 additional
studies identified through
conference proceedings,
2 additional unpublished
data sets provided,personal
contact with 2 additional
studies’ authors
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Fig 1. PRISMA study ﬂow chart.
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Table 1. Summary of Patient and Disease Characteristics According to PIK3CA Mutation Type
Characteristic
PIK3CA Mutation Status
P All PatientsWild Type Mutant
Age (continuous; years) , .001
Mean (SD) 58.4 (12.5) 61.0 (11.6) 59.2 (12.3)
Median (range) 59 (18-95) 61 (21-96) 59.7 (18-96)
Interquartile range 50-67.3 53-69.1 51-68
Unknown 27 12 39
Age (categorical; years) , .001
# 50 1,789 (75.1) 594 (24.9) 2,383 (23.2)
. 50 5,222 (66.1) 2,675 (33.9) 7,897 (76.8)
Unknown 27 12 39
Menopausal status , .001*
Premenopausal 1,174 (76.5) 361 (23.5) 1,535 (19.0)
Perimenopausal 7 (63.6) 4 (36.4) 11 (0.1)
Postmenopausal 4,230 (65.0) 2,282 (35.0) 6,512 (80.8)
Unknown 1,627 634 2,261
Histology , .001
Ductal 4,727 (69.1) 2,111 (30.9) 6,838 (82.2)
Ductal-lobular 137 (57.3) 102 (42.7) 239 (2.9)
Lobular 585 (61.5) 366 (38.5) 951 (11.4)
Other 244 (82.7) 51 (17.3) 295 (3.5)
Unknown 1,345 651 1,996
Local histologic grade (ordered) , .001†
Poorly differentiated/undifferentiated 2,752 (76.2) 861 (23.8) 3,613 (41.1)
Moderately differentiated 2,722 (64.0) 1,528 (36.0) 4,250 (48.3)
Well differentiated 487 (52.3) 445 (47.7) 932 (10.6)
Unknown 1,077 447 1,524
Central histologic grade (ordered) .001†
Poorly differentiated/undifferentiated 128 (75.7) 41 (24.3) 169 (47.1)
Moderately differentiated 108 (69.7) 47 (30.3) 155 (43.2)
Well differentiated 14 (40.0) 21 (60.0) 35 (9.7)
Unknown 6,788 3,172 9,960
ER status , .001
Negative 1,348 (81.7) 301 (18.3) 1,649 (16.1)
Positive 5,627 (65.5) 2,959 (34.5) 8,586 (83.9)
Unknown 63 21 84
PR status , .001
Negative 2,329 (76.0) 736 (24.0) 3,065 (33.2)
Positive 3,970 (64.4) 2,196 (35.6) 6,166 (66.8)
Unknown 739 349 1,088
HER2 status , .001
Negative 5,120 (65.9) 2,648 (34.1) 7,768 (79.7)
Positive 1,540 (77.7) 441 (22.3) 1,981 (20.3)
Unknown 378 192 570
Subtype , .001
HER2 negative/ER negative 790 (82.5) 167 (17.5) 957 (9.8)
HER2 negative/ER positive 4,313 (63.5) 2,475 (36.5) 6,788 (69.8)
HER2 positive 1,540 (77.7) 441 (22.3) 1,981 (20.4)
Unknown 395 198 593
Tumor size (mm) .001
Mean (SD) 26.3 (16.1) 25.00 (14.3) 25.90 (15.5)
Median (range) 23 (0-250) 22 (0-180) 22 (0-250)
Interquartile range 16-30 15-30 16-30
Unknown 622 (71.6%) 247 (28.4%) 869
Tumor size (ordered) , .001†
T0 1 (16.7) 5 (83.3) 6 (0.1)
T1 2,861 (65.4) 1,511 (34.6) 4,372 (43.2)
T2 3,510 (69.8) 1,516 (30.2) 5,026 (49.7)
T3 423 (74.3) 146 (25.7) 569 (5.6)
T4 92 (63.0) 54 (37.0) 146 (1.4)
Unknown 151 49 200
NOTE. Data are represented as No. (%) unless otherwise noted.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard deviation.
*Test included premenopausal and postmenopausal only.
†Test for trend.
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Supplement). Overall, the median age at diagnosis was 60 years
(range, 18 to 95), and the median follow-up time was 6.9 years
(range, 2 days to 21.5 years); 1,787 patients (17%) received
chemotherapy, 4,036 (39%) received endocrine treatment, 3,583
(35%) received both, and 895 (9%) received none or the treatment
was unknown.
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Fig 2. Unadjusted effect of PIK3CA ge-
notype on invasive disease-free survival
(IDFS), distant disease-free survival (DDFS),
and overall survival (OS) by study and for all
pooled data by data set. HR, hazard ratio.
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Associations Between PIK3CA Mutations With
Clinicopathologic Variables
Summary results from the comparison of baseline charac-
teristics and PIK3CAmutation status are listed in Table 1. PIK3CA
mutations were identiﬁed in the tumors of 3,281 patients (32%);
1,705 (52%) of these were in the kinase domain and 1,263 (39%)
were in the helical domain. PIK3CA mutations were more com-
mon in older patients, ER-positive tumors, and lower-grade and
smaller tumors. The frequency of PIK3CA mutations also differed
signiﬁcantly by BC subtypes deﬁned by combined ER and HER2
status (HER2-negative/ER-negative [also known as triple-negative
breast cancer], 18%; HER2-negative/ER-positive [also known as
luminal], 37%; HER2-positive, 22%; P , .001).
Associations Between PIK3CAMutations and Prognosis
In the univariable analysis, PIK3CA mutations were signiﬁ-
cantly associated with better IDFS (HR, 0.77; 95% CI, 0.71 to 0.84;
P , .001; Table 2). Figure 2 shows the estimated HRs and 95% CIs
for each of the studies individually and for all data combined for
IDFS, DDFS, and OS. No signiﬁcant heterogeneity was found
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between studies in the univariable effect of PIK3CA mutation
status on IDFS (PIK3CA genotype by study interaction; P = .12).
For both DDFS and OS, signiﬁcant heterogeneity was found
between studies (P = .004 and P = .009, respectively). Evidence
of departure from the proportional hazards assumption was
observed (P , .001), implying that the effect of PIK3CA ge-
notype on IDFS changed over time. Patients with PIK3CA
mutant tumors had better IDFS during the ﬁrst 10 years after
diagnosis (0 to 5 years: HR, 0.73; 95% CI, 0.66 to 0.81; P, .001; 5 to
10 years: HR, 0.82; 95% CI, 0.68 to 0.99; P = .037) but not after 10
years (HR, 1.15; 95% CI, 0.84 to 1.58; P = .38; P heterogeneity = .02;
Table 2; Fig 3).
There was similar evidence of a nonproportional hazard of
relapse over time for DDFS (P , .001), although not for OS
(P = .27). Of note, the nonproportionality was signiﬁcant only when
all BC subtypes were combined (Data Supplement).
After adjusting for age, tumor size, nodal status, local grade,
ER status, HER2 status, and treatment, PIK3CA status remained
signiﬁcant for IDFS (HR, 0. 88; 95% CI, 0.78 to 1.00; P = .043) but
not for DDFS (P = .054) and OS (P = .8; Table 2).
The effects of PIK3CA genotype on the IDFS and DDFS by BC
subtype can be found in the Data Supplement. Notably, there were
no signiﬁcant interactions observed between PIK3CA mutation
status, BC subtype, and prognosis with the exception of HER2
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disease and OS (IDFS: P = .16; DDFS: P = .39; OS: P = .04; Data
Supplement) where PIK3CA mutations were associated with
a worse OS. Mutation location (helical v kinase domain) also did
not seem to signiﬁcantly affect prognosis (IDFS:P= .74; DDFS: P= .92;
OS P = .65; Data Supplement). In an exploratory analysis, a signiﬁcant
interaction between PIK3CA status and continuous age at diagnosis was
observed for IDFS and OS but not for DDFS (IDFS: P = .032; DDFS:
P = .20; OS: P , .001; shown in Figure 4 using categorized age at
50 years) where younger patients with a mutation had better
survival.
DISCUSSION
The potential prognostic relevance of PIK3CA mutations in early-
stage BC has thus far been unclear. The larger data sets have re-
ported PIK3CA mutations as a favorable aberration, associated
with a better clinical outcome, seemingly somewhat at odds with
the notion of PIK3CA being considered an oncogenic driver.18 Our
study, pooling data from 19 cohorts reaching a total of 10,319
patients, conﬁrms this ﬁnding in the univariable analyses. PIK3CA
mutations were found to be associated with improved IDFS rates
(HR, 0.77; P, .001) in the univariable analysis, but this effect was
less strong in the multivariable model because of its association
with favorable clinicopathologic characteristics, namely, older age,
ER positivity, lower grade, and smaller tumor size. Overall, our
data did not reveal a consistent difference in its prognostic effect
according to BC subtype, with the exception of HER2-positive
disease and the end point of OS.
Preclinical evidence indicates possible biologic differences
between PIK3CA mutations affecting the helical or the kinase
domain.34,35 In particular, mutations of the helical domain have
been associated with a more aggressive phenotype.36 In our pooled
analysis, including 1,263 and 1,705 patients with PIK3CA muta-
tions in the helical and kinase domain, respectively, we found no
signiﬁcant differences in their prognostic impact, similar to studies
previously reported.18,23
Associations with ER positivity remain intriguing. Tikoo
et al37 reported an increase in the luminal progenitor population
in their PIK3CA knock-in mouse model, suggesting that PIK3CA
mutation was important in BC initiation.37 This is supported by
the observation that PIK3CAmutations exist at high frequency in
DCIS.38 Loi et al39 reported decreased mTORC1 signaling as well
as upregulation of ER-related genes at the gene expression level in
PIK3CA mutant ER-positive primary BCs. These data suggest
that PIK3CA mutations could drive oncogenesis through ER
signaling.39 Alternatively, PIK3CA mutations have been associ-
ated with the induction of senescence in BC, with similar ﬁndings
reported in other tumor histologies.40,41 Hence, despite being
a known driver mutation, PIK3CA mutations seem to contribute
to a favorable clinicopathologic phenotype and behave less ag-
gressively than BCs with driver gene ampliﬁcations. These ob-
servations should be distinguished from reports that PI3K
pathway activation per se is associated with endocrine therapy
resistance.42
Of note, we conﬁrm a previous observation that the positive
prognostic relevance of PIK3CA mutations is nonproportional,
that is, the strongest effect is in the ﬁrst 5 years and decreases over
time. The explanation for this remains unclear.17 However, we note
that the proportion of patients with over 10 years of follow-up is
, 10% and critically does not exclude (lower bound of HR, 0.84)
better IDFS; therefore, the departure from proportional hazards
could be due to either a reduction in beneﬁt over time or a loss of
this effect, or bias in patients with longer follow-up. Taking into
account the natural history of BC and the latency of the disease,
with relapses occurring even after considerable time after the
primary diagnosis, the median follow-up of patients in our pooled
analysis (6.9 years) should be taken into consideration when
interpreting the results. We also observed a signiﬁcant interaction
between age and PI3KCA mutation status. It would be valuable to
further validate this ﬁnding in adjuvant endocrine studies of
premenopausal women.43
Our study has signiﬁcant strengths, namely, that it is the
largest to date performed in patients with early-stage BC using
large data sets derived from prospective randomized clinical trials
with the use of individual patient-level data. Of note, the size of this
data set enabled us to assess the prognostic relevance of PIK3CA
mutations across all subtypes of BC, and the use of prospective
clinical trial data sets may overcome some biases inherent in
retrospective institutional series. We acknowledge the limitations:
(1) signiﬁcant heterogeneity among data sets; (2) the treatments
administered did not follow a set protocol; in particular, some of
the patients with HER2-positive BC did not receive (neo)adjuvant
trastuzumab-based treatment, and some of the treatments ad-
ministered differed from current standards (Data Supplement); (3)
only articles published in Englishwere included; (4) only published
studies were included (ie, possible bias toward positive results); and
(5) heterogeneity in terms of methods of assessment of PIK3CA
mutation status.
In summary, our results indicate that PIK3CA somatic mu-
tations are associated with a signiﬁcantly better clinical outcome in
the univariable but to a lesser extent in the multivariable analysis in
early-stage BC. Next-generation sequencing studies have reported
that PIK3CAmutations often coexist with other genetic alterations.44
Integration of coexistent genetic alterations and, potentially, plasma
analyses and other markers of PI3K pathway activation will better
reﬁne prognostic assessments of PIK3CA mutant early-stage BC
patients.
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